Benson, C, Vitfell-Rasmussen, J, Maruzzo, M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014;34:3663–8.Google Scholar

Burgess, M, Tawbi, H. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol. 2015;16:26.Google Scholar

Butrynski, JE, D’Adamo, DR, Hornick, JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–33.CrossRefGoogle ScholarPubMed

Casali, PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol. 2012;23 Suppl 10:x167–9.CrossRefGoogle ScholarPubMed

Casali, PG. Adjuvant chemotherapy for soft tissue sarcoma. Am Soc Clin Oncol Educ Book. 2015;35:e629–33.Google Scholar

Casali, PG, Bruzzi, P, Bogaerts, J, Blay, JY; on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26:300–306.Google Scholar

Casali, PG, Dei Tos, AP, Gronchi, A. Gastrointestinal stromal tumor. In: DeVita, VT, Lawrence, TS, Rosenberg, SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2014.Google Scholar

Casali, PG, Le Cesne, A, Poveda Velasco, A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33:4276–83.Google Scholar

DeMatteo, RP, Ballman, KV, Antonescu, CR, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373: 1097–104.CrossRefGoogle ScholarPubMed

Demetri, GD, Jeffers, M, Reichardt, P, et al. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. J Clin Oncol. 2013;31: Suppl, abstr 10503 (meeting abstract)CrossRefGoogle Scholar

Demetri, GD, Reichardt, P, Kang, YK, et al; GRID Study Investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.Google Scholar

Demetri, GD, van Oosterom, AT, Garrett, CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.Google Scholar

Demetri, GD, von Mehren, M, Jones, RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2015 Sep;14:pii: JCO.2015.62.4734. [Epub ahead of print]Google Scholar

D’Angelo, SP, Tap, WD, Schwartz, GK, Carvajal, RD. Sarcoma immunotherapy: past approaches and future directions. Sarcoma. 2014;2014:391967.Google ScholarPubMed

D’Angelo, SP, Shoushtari, AN, Agaram, NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357–65.CrossRefGoogle ScholarPubMed

Di Giandomenico, S, Frapolli, R, Bello, E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014;33:5201–10.Google Scholar

Frustaci, S, Gherlinzoni, F, De Paoli, A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19: 1238–47.CrossRefGoogle ScholarPubMed

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247–53.Google Scholar

Gold, JS, Gonen, M, Gutierrez, A, et al. Development and validation of a prognostic nomongram for recurrence-free survival after complete surgical resection of localized primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.Google Scholar

Gronchi, A, Colombo, C, Le Péchoux, C, et al; ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm – a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25:578–83.Google Scholar

Gronchi, A, Ferrari, S, Quagliuolo, V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22.Google Scholar

Grosso, F, Jones, RL, Demetri, GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602.CrossRefGoogle ScholarPubMed

Heinrich, MC, Maki, RG, Corless, CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.Google Scholar

Joensuu, H. Risk stratification of patients diagnosed with gastrointestinal stromal tumors. Hum Pathol. 2008;39:1411–19.CrossRefGoogle Scholar

Joensuu, H, Eriksson, M, Sundby Hall, K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244–50.CrossRefGoogle ScholarPubMed

Joensuu, H, Vehtari, A, Riihimäki, J, et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.Google Scholar

Judson, I, Verweij, J, Gelderblom, H, et al; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.Google Scholar

Kang, YK, Ryu, MH, Yoo, C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175–82.Google Scholar

Maki, RG, Wathen, JK, Patel, SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.Google Scholar

Miettinen, M, Lasota, J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.Google Scholar

Palassini, E, Ferrari, S, Verderio, P, et al. Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: three versus five cycles of full-dose epirubicin plus ifosfamide. J Clin Oncol. 2015;33:3628–34.Google Scholar

Patrikidou, A, Chabaud, S, Ray-Coquard, I, et al; French Sarcoma Group. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol. 2013;24:1087–93.CrossRefGoogle ScholarPubMed

Pautier, P, Floquet, A, Penel, N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17(9):1213–20.CrossRefGoogle Scholar

Pervaiz, N, Colterjohn, N, Farrokhyar, F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.CrossRefGoogle ScholarPubMed

Postow, MA, Callahan, MK, Wolchok, JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82.Google Scholar

Ray-Coquard, I, Blay, JY, Italiano, A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133–40.Google Scholar

Robbins, PF, Morgan, RA, Feldman, SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–24.Google Scholar

Rossi, S, Miceli, R, Messerini, L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011;35:1646–56.CrossRefGoogle ScholarPubMed

Rutkowski, P, Gronchi, A, Hohenberger, P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–43.Google Scholar

Sanfilippo, R, Bertulli, R, Marrari, A, et al. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res. 2014;4:16.Google Scholar

Singer, S, Tap, WD, Crago, AM, O’Sullivan, B. Soft tissue sarcoma. In: DeVita, VT, Lawrence, TS, Rosenberg, SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2014.Google Scholar

Stacchiotti, S, Marrari, A, Dei Tos, AP, Casali, PG. Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS. Hematol Oncol Clin North Am. 2013;27:1049–61.CrossRefGoogle ScholarPubMed

Stacchiotti, S, Negri, T, Libertini, M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23:3171–9.Google Scholar

Stacchiotti, S, Negri, T, Zaffaroni, N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–90.CrossRefGoogle ScholarPubMed

Stacchiotti, S, Palassini, E, Sanfilippo, R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23:501–8.Google Scholar

Stacchiotti, S, Pantaleo, MA, Astolfi, A, et al. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. Eur J Cancer. 2014;50:1657–64.Google Scholar

Stacchiotti, S, Pantaleo, MA, Negri, T, et al. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). Clin Cancer Res. 2016;22:938–46.CrossRefGoogle ScholarPubMed

Stacchiotti, S, Verderio, P, Messina, A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118:5857–66.Google Scholar

Tawbi, HA, Burgess, M, Bolejack, V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493–1501.CrossRefGoogle ScholarPubMed

van der Graaf, WT, Blay, JY, Chawla, SP, et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.Google Scholar

Verweij, J, Casali, PG, Zalcberg, J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.Google Scholar

Wang, WL, Conley, A, Reynoso, D, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011;67 Suppl 1:S15–24.Google Scholar

Wang, WL, Katz, D, Araujo, DM, et al. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res. 2012;2:25.Google Scholar

Wardelmann, E, Merkelbach-Bruse, S, Pauls, K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743–9.Google Scholar